Xponance Inc. bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 13,132 shares of the company’s stock, valued at approximately $98,000.
Other hedge funds also recently made changes to their positions in the company. ARK Investment Management LLC lifted its stake in Recursion Pharmaceuticals by 14.5% during the second quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock worth $211,072,000 after purchasing an additional 3,555,357 shares during the last quarter. Baillie Gifford & Co. lifted its position in shares of Recursion Pharmaceuticals by 10.5% in the 2nd quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after buying an additional 2,522,132 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Recursion Pharmaceuticals by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company’s stock worth $159,667,000 after buying an additional 349,554 shares during the last quarter. Mubadala Investment Co PJSC bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $128,041,000. Finally, Kinnevik AB publ raised its stake in Recursion Pharmaceuticals by 14.4% during the second quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock worth $89,293,000 after acquiring an additional 1,500,000 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.
Insider Buying and Selling
In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $8.48, for a total value of $97,070.56. Following the completion of the sale, the director now directly owns 7,155,663 shares of the company’s stock, valued at approximately $60,680,022.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $8.48, for a total transaction of $97,070.56. Following the completion of the sale, the director now owns 7,155,663 shares in the company, valued at approximately $60,680,022.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $7.00, for a total value of $42,000.00. Following the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at $3,647,966. The disclosure for this sale can be found here. Insiders have sold a total of 231,682 shares of company stock valued at $1,632,044 over the last three months. Company insiders own 15.75% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Report on RXRX
Recursion Pharmaceuticals Trading Down 1.0 %
Shares of NASDAQ:RXRX opened at $6.11 on Thursday. The company has a 50 day moving average of $6.92 and a 200-day moving average of $8.11. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.72 billion, a P/E ratio of -3.82 and a beta of 0.82. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.97 and a twelve month high of $15.74.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same quarter last year, the company earned ($0.38) earnings per share. The business’s revenue for the quarter was up 30.9% on a year-over-year basis. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
- Five stocks we like better than Recursion Pharmaceuticals
- ESG Stocks, What Investors Should Know
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- What does consumer price index measure?
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Business Services Stocks Investing
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report).
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.